DOI QR코드

DOI QR Code

Growth Hormone Therapy in PWS with Mobile Application-Living with PWS

  • Im, Minji (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 투고 : 2018.11.26
  • 심사 : 2018.12.14
  • 발행 : 2018.12.31

초록

Prader-Willi syndrome (PWS) is a multisystemic complex disorder characterized by hyperphagia and impaired satiety which lead to severe and early obesity. In infancy, hypotonia and poor suck are main problems, and a child goes through Failure-to-thrive. During childhood, clinical manifestations change to food seeking as well as excessive weight gain, short stature, developmental delay, cognitive disability and behavioral problems. Also, growth hormone insufficiency is frequent. Most patients receive the recombinant growth hormone (rGH) therapy that provides improvement in growth, body composition, and physical attributes. The clinical care guideline for rGH therapy in PWS had been noticed in 2013. The rGH therapy helps in body fat, lean body mass, height SDS and head circumference. Also, the rGH therapy helps motor function, psychomotor development and cognition and behavioral issues.In Samsung medical center, there are clinical care guidelines for rGH therapy in PWS and an useful application for the patients. 'Living with PWS', the name of an moblie application for PWS patients, was introduced in the lecture. The application revised to version 2. It was made more convenient to users than in version 1. It helps caregivers to schedule the rGH therapy and to monitor height and weight.

키워드

참고문헌

  1. Prader ALA, Willi H. Ein syndrom von adipositas, kleinwuchs, kryptorchismus und ologophrenie nach myotonicartigem zustand in neurogeborenalter. Schweiz Med Wochenschr 1956;86:1260-61.
  2. Glenn CC, Driscoll DJ, Yang TP, Nicholls RD. Genomic imprinting: potential function and mechanisms revealed by the Prader-Willi and Angelman syndromes. Mol Hum Reprod 1997;3:321-32. https://doi.org/10.1093/molehr/3.4.321
  3. Emerick JE, Vogt KS. Endocrine manifestations and management of Prader-Willi syndrome. Int J Pediatr Endocrinol 2013;2013:14. https://doi.org/10.1186/1687-9856-2013-14
  4. Jin DK. Endocrine problems in children with Prader-Willi syndrome: special review on associated genetic aspects and early growth hormone treatment. Korean J Pediatr 2012;55:224-31. https://doi.org/10.3345/kjp.2012.55.7.224
  5. Wolfgram PM, Carrel AL, Allen DB. Long-term effects of recombinant human growth hormone therapy in children with Prader-Willi syndrome. Curr Opin Pediatr 2013;25:509-14. https://doi.org/10.1097/MOP.0b013e328362c7a2
  6. Deal CL, Tony M, Hoybye C, Allen DB, Tauber M, Christiansen JS. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 2013;98:E1072-87. https://doi.org/10.1210/jc.2012-3888
  7. Roderick FW, Elbrich PS, Dederieke AF, Barto JO, Edgar GM, Joost R, et al. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2009;94:4205-15. https://doi.org/10.1210/jc.2009-0454
  8. Angulo MA, Castro-Magana M, Lamerson M, Arguello R, Accacha S, Khan A. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am J Med Genet A 2007;143A:1456-61. https://doi.org/10.1002/ajmg.a.31824
  9. Deal CL, Tony M, Hoybye C, Allen DB, Tauber M, Christiansen JS. Growth hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013 Jun; 98: E1072-E1087. https://doi.org/10.1210/jc.2012-3888